Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Publication Category: Medications

Could signal transducer and activator of transcription 3 be a therapeutic target in obesity-related gastrointestinal malignancy?

K. E. O'Sullivan; J. V. Reynolds; C. O'Hanlon; J. N. O'Sullivan; J. Lysaght Could signal transducer and activator of transcription 3 be a therapeutic target in obesity-related gastrointestinal malignancy? J Gastrointest Cancer

Beneficial effects of tigerinin-1R on glucose homeostasis and beta cell function in mice with diet-induced obesity-diabetes

O. O. Ojo; D. K. Srinivasan; B. O. Owolabi; P. R. Flatt; Y. H. A. Abdel-Wahab Beneficial effects of tigerinin-1R on glucose homeostasis and beta cell function in mice with diet-induced obesity-diabetes Biochimie
Appetite & Satiety Insulin Resistance & Diabetes

Emerging therapeutic potential for peptide YY for obesity-diabetes

R. A. Lafferty; P. R. Flatt; N. Irwin Emerging therapeutic potential for peptide YY for obesity-diabetes Peptides
Insulin Resistance & Diabetes

Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes

R. A. Lafferty; P. R. Flatt; N. Irwin Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes Curr Opin Endocrinol Diabetes Obes
Insulin Resistance & Diabetes

A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation

A. M. Lynch; N. Pathak; V. Pathak; F. P. M. O’Harte; P. R. Flatt; N. Irwin; V. A. Gault A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation Diabetologia

Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice

N. Irwin; I. A. Montgomery; R. C. Moffett; P. R. Flatt Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice Biochem Pharmacol
Insulin Resistance & Diabetes

Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes

N. Irwin; I. A. Montgomery; F. P. O'Harte; P. Frizelle; P. R. Flatt Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes Int J Obes (Lond)
Insulin Resistance & Diabetes

Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes

N. Irwin; V. A. Gault; F. P. M. O'Harte; P. R. Flatt Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes Peptides
Insulin Resistance & Diabetes

New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders

N. Irwin; P. R. Flatt New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders World J Diabetes
Insulin Resistance & Diabetes

Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient cohort according to BMI

D. Gibeon; K. Batuwita; M. Osmond; L. G. Heaney; C. E. Brightling; R. Niven; A. Mansur; R. Chaudhuri; C. E. Bucknall; A. Rowe; Y. Guo; P. K. Bhavsar; K. F. Chung; A. Menzies-Gow Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient cohort according to BMI Chest

Older posts

Newer posts

← Previous Page1 … Page6 Page7 Page8 … Page18 Next →

Search for:

Recent Posts

9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO
ECO 2023 sponsorship update

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Menu

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2024 ASOI